Abstract
Patients with chronic inflammatory diseases such as rheumatoid arthritis have a higher risk of cardiovascular diseases and related mortality compared to the general population. This risk is first due to classical cardiovascular risk factors but also due to systemic inflammation which is independently involved, causing accelerated atherosclerosis, myocardial infarction, cerebrovascular disease and heart failure (HF). Pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1 and IL-6 could be major actors on this pathophysiology. Biologics are effective specific treatments in the management of inflammatory rheumatic and systemic diseases. In this review, beneficial and deleterious effects on the heart and vessels of the biologics used in the management of inflammatory arthritis and vasculitides will be discussed, focusing on TNF-alpha, IL-6 and IL-1 blockades, and anti-CD20. Noninflammatory cardiac conditions, such as heart failure, myocardial infarction, and cardiovascular conditions such as atherosclerosis, as well as inflammatory diseases including vasculitides will be discussed.
Keywords: Cardiovascular disease, inflammation, biologics, TNF-alpha, IL-1, IL-6, cytokines, atherosclerosis, heart failure
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title:Biologics and the Cardiovascular System: A Double-Edged Sword
Volume: 12 Issue: 1
Author(s): Camille Roubille, Johanne Martel-Pelletier, Boulos Haraoui, Jean-Claude Tardif and Jean-Pierre Pelletier
Affiliation:
Keywords: Cardiovascular disease, inflammation, biologics, TNF-alpha, IL-1, IL-6, cytokines, atherosclerosis, heart failure
Abstract: Patients with chronic inflammatory diseases such as rheumatoid arthritis have a higher risk of cardiovascular diseases and related mortality compared to the general population. This risk is first due to classical cardiovascular risk factors but also due to systemic inflammation which is independently involved, causing accelerated atherosclerosis, myocardial infarction, cerebrovascular disease and heart failure (HF). Pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1 and IL-6 could be major actors on this pathophysiology. Biologics are effective specific treatments in the management of inflammatory rheumatic and systemic diseases. In this review, beneficial and deleterious effects on the heart and vessels of the biologics used in the management of inflammatory arthritis and vasculitides will be discussed, focusing on TNF-alpha, IL-6 and IL-1 blockades, and anti-CD20. Noninflammatory cardiac conditions, such as heart failure, myocardial infarction, and cardiovascular conditions such as atherosclerosis, as well as inflammatory diseases including vasculitides will be discussed.
Export Options
About this article
Cite this article as:
Roubille Camille, Martel-Pelletier Johanne, Haraoui Boulos, Tardif Jean-Claude and Pelletier Jean-Pierre, Biologics and the Cardiovascular System: A Double-Edged Sword, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2013; 12 (1) . https://dx.doi.org/10.2174/1871523011312010009
DOI https://dx.doi.org/10.2174/1871523011312010009 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Renin-Angiotensin System in Inflammation, Immunity and Aging
Current Pharmaceutical Design Hydroxychloroquine and Azithromycin Combination in the Management of COVID-19 Infection: Safety and Effectiveness Challenges
Current Drug Safety Ghrelin Based Therapy of Metabolic Diseases
Current Medicinal Chemistry Patent Selections
Recent Patents on Cardiovascular Drug Discovery RAGE: A Multi-Ligand Receptor Unveiling Novel Insights in Health and Disease
Current Medicinal Chemistry Functional Signaling Biases in G Protein-Coupled Receptors: Game Theory and Receptor Dynamics
Mini-Reviews in Medicinal Chemistry P2Y Purinoceptors as Potential Emerging Therapeutical Target in Vascular Disease
Current Pharmaceutical Design Computational Advances in Chronic Diseases Diagnostics and Therapy - II
Current Drug Targets Digoxin in Atrial Fibrillation: An Old Topic Revisited
Current Cardiology Reviews Can γH2AX be Used to Personalise Cancer Treatment?
Current Molecular Medicine Hypertensive Heart Disease and the Role of Aldosterone Antagonists
Current Hypertension Reviews Obstructive Sleep Apnea and Atrial Arrhythmogenesis
Current Cardiology Reviews Hyperhomocysteinemia and Sudden Cardiac Death: Potential Arrhythmogenic Mechanisms
Current Vascular Pharmacology Antibiotic Susceptibility and Treatment of Brucellosis
Recent Patents on Anti-Infective Drug Discovery Thrombotic Thrombocytopenic Purpura and Anti-Thrombotic Therapy Targeted to Von Willebrand Factor
Current Vascular Pharmacology Histone Deacetylase Inhibitors and Neurodegenerative Disorders: Holding the Promise
Current Pharmaceutical Design Antioxidant Effects of Natural Bioactive Compounds
Current Pharmaceutical Design Therapeutic Potential of Plant Extracts and Phytochemicals Against Brain Ischemia-Reperfusion Injury: A Review
The Natural Products Journal New Pharmacologic Approaches to Prevent Thromboembolism in Patients with Atrial Fibrillation
Current Vascular Pharmacology Application of NMR Metabolomics to Search for Human Disease Biomarkers
Combinatorial Chemistry & High Throughput Screening